Fan Shanmin, Yuan Yang, Su Yanfang, Sang Die
Department of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Beijing, China.
Department of Pathology, Emergency General Hospital, Beijing, China.
SAGE Open Med Case Rep. 2025 Jan 27;13:2050313X241313084. doi: 10.1177/2050313X241313084. eCollection 2025.
Anaplastic thyroid carcinoma (ATC) is one rare type of thyroid carcinoma without standard systemic treatment for advanced disease. Recent evidence has demonstrated promising efficacy of immune checkpoint inhibitors, particularly those targeting programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1), in a variety of solid tumors. However, there have been no research of immune checkpoint inhibitors plus chemotherapy in ATC. Here, we present the case of a 37-year-old man with metastatic ATC with positive PD-L1 expression, who achieved long-term remission of 34 months after later-line treatment with zimberelimab (a PD-1 inhibitor) and nab-paclitaxel, followed by single-agent zimberelimab maintenance therapy. After three cycles of the combination treatment, the thyroid lesion and the liver metastases shrank dramatically, leading to the best overall response of partial remission. PD-L1 expression may serve as a potential biomarker for tumor response to immune checkpoint inhibitors in ATC. Our review highlights the need for further studies investigating the role of PD-L1 status as biomarker to predict the prognosis of immunotherapy in the treatment of ATC.
间变性甲状腺癌（ATC）是一种罕见的甲状腺癌，晚期疾病尚无标准的全身治疗方法。最近的证据表明，免疫检查点抑制剂，尤其是那些靶向程序性死亡-1（PD-1）/程序性死亡配体1（PD-L1）的抑制剂，在多种实体瘤中显示出有前景的疗效。然而，尚未有关于免疫检查点抑制剂联合化疗治疗ATC的研究。在此，我们报告一例37岁转移性ATC男性患者，其PD-L1表达呈阳性，在接受替雷利珠单抗（一种PD-1抑制剂）和白蛋白结合型紫杉醇进行后线治疗，随后接受替雷利珠单抗单药维持治疗后，实现了34个月的长期缓解。联合治疗三个周期后，甲状腺病变和肝转移灶显著缩小，导致最佳总体反应为部分缓解。PD-L1表达可能作为ATC中肿瘤对免疫检查点抑制剂反应的潜在生物标志物。我们的综述强调需要进一步研究，以探讨PD-L1状态作为生物标志物在预测免疫治疗对ATC治疗预后中的作用。
